 | • レポートコード：MRC308GR11340 • 出版社/出版日：GlobalInfoResearch / 2023年8月 2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥528,960 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥793,440 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界の急性ウイルス性鼻副鼻腔炎治療の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の急性ウイルス性鼻副鼻腔炎治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– 急性ウイルス性鼻副鼻腔炎治療の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
急性ウイルス性鼻副鼻腔炎治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・NSAIDS、生理食塩水点鼻薬、鼻副腎皮質ステロイド、鼻づまり薬
用途別セグメント
・オフライン薬局、電子商取引
主要な市場プレーヤー
・Sun Pharmaceutical Industries, Inc.、Pfizer, Inc.、Johnson & Johnson、Fresenius Kabi USA, LLC、Dr. Reddy’s Laboratories, Inc.、Novartis AG、Teva Pharmaceutical Industries Ltd.、Sanofi、Abbott Laboratories、Bayer AG、Eli Lilly and Company、Bristol-Myers Squibb、Merck & Co, Inc.、AstraZeneca plc、Amneal Pharmaceuticals LLC、GlaxoSmithKline plc、Aurobindo Pharma、Hikma Pharmaceuticals plc、Wockhardt、Mylan N.V.
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、急性ウイルス性鼻副鼻腔炎治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な急性ウイルス性鼻副鼻腔炎治療メーカーの企業概要、2019年～2022年までの急性ウイルス性鼻副鼻腔炎治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な急性ウイルス性鼻副鼻腔炎治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別急性ウイルス性鼻副鼻腔炎治療の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの急性ウイルス性鼻副鼻腔炎治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での急性ウイルス性鼻副鼻腔炎治療市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および急性ウイルス性鼻副鼻腔炎治療の産業チェーンを掲載しています。
・第14、15章では、急性ウイルス性鼻副鼻腔炎治療の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– 急性ウイルス性鼻副鼻腔炎治療の概要
– 種類別分析（2018年vs2022年vs2029年）：NSAIDS、生理食塩水点鼻薬、鼻副腎皮質ステロイド、鼻づまり薬
– 用途別分析（2018年vs2022年vs2029年）：オフライン薬局、電子商取引
– 世界の急性ウイルス性鼻副鼻腔炎治療市場規模・予測
– 世界の急性ウイルス性鼻副鼻腔炎治療生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Sun Pharmaceutical Industries, Inc.、Pfizer, Inc.、Johnson & Johnson、Fresenius Kabi USA, LLC、Dr. Reddy’s Laboratories, Inc.、Novartis AG、Teva Pharmaceutical Industries Ltd.、Sanofi、Abbott Laboratories、Bayer AG、Eli Lilly and Company、Bristol-Myers Squibb、Merck & Co, Inc.、AstraZeneca plc、Amneal Pharmaceuticals LLC、GlaxoSmithKline plc、Aurobindo Pharma、Hikma Pharmaceuticals plc、Wockhardt、Mylan N.V.
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：NSAIDS、生理食塩水点鼻薬、鼻副腎皮質ステロイド、鼻づまり薬
・用途別分析2018年-2029年：オフライン薬局、電子商取引
・急性ウイルス性鼻副鼻腔炎治療の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・急性ウイルス性鼻副鼻腔炎治療のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・急性ウイルス性鼻副鼻腔炎治療のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・急性ウイルス性鼻副鼻腔炎治療の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・急性ウイルス性鼻副鼻腔炎治療の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Acute Viral Rhinosinusitis Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Acute Viral Rhinosinusitis Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 NSAIDS
1.3.3 Saline Nasal Spray
1.3.4 Nasal Corticosteroids
1.3.5 Decongestants
1.4 Market Analysis by Application
1.4.1 Overview: Global Acute Viral Rhinosinusitis Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Offline Pharmacy
1.4.3 E-Commerce
1.5 Global Acute Viral Rhinosinusitis Treatment Market Size & Forecast
1.5.1 Global Acute Viral Rhinosinusitis Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Acute Viral Rhinosinusitis Treatment Sales Quantity (2018-2029)
1.5.3 Global Acute Viral Rhinosinusitis Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Sun Pharmaceutical Industries, Inc.
2.1.1 Sun Pharmaceutical Industries, Inc. Details
2.1.2 Sun Pharmaceutical Industries, Inc. Major Business
2.1.3 Sun Pharmaceutical Industries, Inc. Acute Viral Rhinosinusitis Treatment Product and Services
2.1.4 Sun Pharmaceutical Industries, Inc. Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sun Pharmaceutical Industries, Inc. Recent Developments/Updates
2.2 Pfizer, Inc.
2.2.1 Pfizer, Inc. Details
2.2.2 Pfizer, Inc. Major Business
2.2.3 Pfizer, Inc. Acute Viral Rhinosinusitis Treatment Product and Services
2.2.4 Pfizer, Inc. Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer, Inc. Recent Developments/Updates
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Acute Viral Rhinosinusitis Treatment Product and Services
2.3.4 Johnson & Johnson Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Johnson & Johnson Recent Developments/Updates
2.4 Fresenius Kabi USA, LLC
2.4.1 Fresenius Kabi USA, LLC Details
2.4.2 Fresenius Kabi USA, LLC Major Business
2.4.3 Fresenius Kabi USA, LLC Acute Viral Rhinosinusitis Treatment Product and Services
2.4.4 Fresenius Kabi USA, LLC Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Fresenius Kabi USA, LLC Recent Developments/Updates
2.5 Dr. Reddy’s Laboratories, Inc.
2.5.1 Dr. Reddy’s Laboratories, Inc. Details
2.5.2 Dr. Reddy’s Laboratories, Inc. Major Business
2.5.3 Dr. Reddy’s Laboratories, Inc. Acute Viral Rhinosinusitis Treatment Product and Services
2.5.4 Dr. Reddy’s Laboratories, Inc. Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Dr. Reddy’s Laboratories, Inc. Recent Developments/Updates
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Acute Viral Rhinosinusitis Treatment Product and Services
2.6.4 Novartis AG Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Novartis AG Recent Developments/Updates
2.7 Teva Pharmaceutical Industries Ltd.
2.7.1 Teva Pharmaceutical Industries Ltd. Details
2.7.2 Teva Pharmaceutical Industries Ltd. Major Business
2.7.3 Teva Pharmaceutical Industries Ltd. Acute Viral Rhinosinusitis Treatment Product and Services
2.7.4 Teva Pharmaceutical Industries Ltd. Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Acute Viral Rhinosinusitis Treatment Product and Services
2.8.4 Sanofi Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Sanofi Recent Developments/Updates
2.9 Abbott Laboratories
2.9.1 Abbott Laboratories Details
2.9.2 Abbott Laboratories Major Business
2.9.3 Abbott Laboratories Acute Viral Rhinosinusitis Treatment Product and Services
2.9.4 Abbott Laboratories Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Abbott Laboratories Recent Developments/Updates
2.10 Bayer AG
2.10.1 Bayer AG Details
2.10.2 Bayer AG Major Business
2.10.3 Bayer AG Acute Viral Rhinosinusitis Treatment Product and Services
2.10.4 Bayer AG Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Bayer AG Recent Developments/Updates
2.11 Eli Lilly and Company
2.11.1 Eli Lilly and Company Details
2.11.2 Eli Lilly and Company Major Business
2.11.3 Eli Lilly and Company Acute Viral Rhinosinusitis Treatment Product and Services
2.11.4 Eli Lilly and Company Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Eli Lilly and Company Recent Developments/Updates
2.12 Bristol-Myers Squibb
2.12.1 Bristol-Myers Squibb Details
2.12.2 Bristol-Myers Squibb Major Business
2.12.3 Bristol-Myers Squibb Acute Viral Rhinosinusitis Treatment Product and Services
2.12.4 Bristol-Myers Squibb Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Bristol-Myers Squibb Recent Developments/Updates
2.13 Merck & Co, Inc.
2.13.1 Merck & Co, Inc. Details
2.13.2 Merck & Co, Inc. Major Business
2.13.3 Merck & Co, Inc. Acute Viral Rhinosinusitis Treatment Product and Services
2.13.4 Merck & Co, Inc. Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Merck & Co, Inc. Recent Developments/Updates
2.14 AstraZeneca plc
2.14.1 AstraZeneca plc Details
2.14.2 AstraZeneca plc Major Business
2.14.3 AstraZeneca plc Acute Viral Rhinosinusitis Treatment Product and Services
2.14.4 AstraZeneca plc Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 AstraZeneca plc Recent Developments/Updates
2.15 Amneal Pharmaceuticals LLC
2.15.1 Amneal Pharmaceuticals LLC Details
2.15.2 Amneal Pharmaceuticals LLC Major Business
2.15.3 Amneal Pharmaceuticals LLC Acute Viral Rhinosinusitis Treatment Product and Services
2.15.4 Amneal Pharmaceuticals LLC Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Amneal Pharmaceuticals LLC Recent Developments/Updates
2.16 GlaxoSmithKline plc
2.16.1 GlaxoSmithKline plc Details
2.16.2 GlaxoSmithKline plc Major Business
2.16.3 GlaxoSmithKline plc Acute Viral Rhinosinusitis Treatment Product and Services
2.16.4 GlaxoSmithKline plc Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 GlaxoSmithKline plc Recent Developments/Updates
2.17 Aurobindo Pharma
2.17.1 Aurobindo Pharma Details
2.17.2 Aurobindo Pharma Major Business
2.17.3 Aurobindo Pharma Acute Viral Rhinosinusitis Treatment Product and Services
2.17.4 Aurobindo Pharma Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Aurobindo Pharma Recent Developments/Updates
2.18 Hikma Pharmaceuticals plc
2.18.1 Hikma Pharmaceuticals plc Details
2.18.2 Hikma Pharmaceuticals plc Major Business
2.18.3 Hikma Pharmaceuticals plc Acute Viral Rhinosinusitis Treatment Product and Services
2.18.4 Hikma Pharmaceuticals plc Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Hikma Pharmaceuticals plc Recent Developments/Updates
2.19 Wockhardt
2.19.1 Wockhardt Details
2.19.2 Wockhardt Major Business
2.19.3 Wockhardt Acute Viral Rhinosinusitis Treatment Product and Services
2.19.4 Wockhardt Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Wockhardt Recent Developments/Updates
2.20 Mylan N.V.
2.20.1 Mylan N.V. Details
2.20.2 Mylan N.V. Major Business
2.20.3 Mylan N.V. Acute Viral Rhinosinusitis Treatment Product and Services
2.20.4 Mylan N.V. Acute Viral Rhinosinusitis Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Mylan N.V. Recent Developments/Updates
3 Competitive Environment: Acute Viral Rhinosinusitis Treatment by Manufacturer
3.1 Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Acute Viral Rhinosinusitis Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Acute Viral Rhinosinusitis Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Acute Viral Rhinosinusitis Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Acute Viral Rhinosinusitis Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Acute Viral Rhinosinusitis Treatment Manufacturer Market Share in 2022
3.5 Acute Viral Rhinosinusitis Treatment Market: Overall Company Footprint Analysis
3.5.1 Acute Viral Rhinosinusitis Treatment Market: Region Footprint
3.5.2 Acute Viral Rhinosinusitis Treatment Market: Company Product Type Footprint
3.5.3 Acute Viral Rhinosinusitis Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Acute Viral Rhinosinusitis Treatment Market Size by Region
4.1.1 Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Acute Viral Rhinosinusitis Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Acute Viral Rhinosinusitis Treatment Average Price by Region (2018-2029)
4.2 North America Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029)
4.3 Europe Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029)
4.5 South America Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2029)
5.2 Global Acute Viral Rhinosinusitis Treatment Consumption Value by Type (2018-2029)
5.3 Global Acute Viral Rhinosinusitis Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2029)
6.2 Global Acute Viral Rhinosinusitis Treatment Consumption Value by Application (2018-2029)
6.3 Global Acute Viral Rhinosinusitis Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2029)
7.2 North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2029)
7.3 North America Acute Viral Rhinosinusitis Treatment Market Size by Country
7.3.1 North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Acute Viral Rhinosinusitis Treatment Market Size by Country
8.3.1 Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Acute Viral Rhinosinusitis Treatment Market Size by Region
9.3.1 Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Acute Viral Rhinosinusitis Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2029)
10.2 South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2029)
10.3 South America Acute Viral Rhinosinusitis Treatment Market Size by Country
10.3.1 South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Size by Country
11.3.1 Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Acute Viral Rhinosinusitis Treatment Market Drivers
12.2 Acute Viral Rhinosinusitis Treatment Market Restraints
12.3 Acute Viral Rhinosinusitis Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Acute Viral Rhinosinusitis Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Acute Viral Rhinosinusitis Treatment
13.3 Acute Viral Rhinosinusitis Treatment Production Process
13.4 Acute Viral Rhinosinusitis Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Acute Viral Rhinosinusitis Treatment Typical Distributors
14.3 Acute Viral Rhinosinusitis Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Sun Pharmaceutical Industries, Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Sun Pharmaceutical Industries, Inc. Major Business
Table 5. Sun Pharmaceutical Industries, Inc. Acute Viral Rhinosinusitis Treatment Product and Services
Table 6. Sun Pharmaceutical Industries, Inc. Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Sun Pharmaceutical Industries, Inc. Recent Developments/Updates
Table 8. Pfizer, Inc. Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer, Inc. Major Business
Table 10. Pfizer, Inc. Acute Viral Rhinosinusitis Treatment Product and Services
Table 11. Pfizer, Inc. Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Pfizer, Inc. Recent Developments/Updates
Table 13. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 14. Johnson & Johnson Major Business
Table 15. Johnson & Johnson Acute Viral Rhinosinusitis Treatment Product and Services
Table 16. Johnson & Johnson Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Johnson & Johnson Recent Developments/Updates
Table 18. Fresenius Kabi USA, LLC Basic Information, Manufacturing Base and Competitors
Table 19. Fresenius Kabi USA, LLC Major Business
Table 20. Fresenius Kabi USA, LLC Acute Viral Rhinosinusitis Treatment Product and Services
Table 21. Fresenius Kabi USA, LLC Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Fresenius Kabi USA, LLC Recent Developments/Updates
Table 23. Dr. Reddy's Laboratories, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Dr. Reddy's Laboratories, Inc. Major Business
Table 25. Dr. Reddy's Laboratories, Inc. Acute Viral Rhinosinusitis Treatment Product and Services
Table 26. Dr. Reddy's Laboratories, Inc. Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Dr. Reddy's Laboratories, Inc. Recent Developments/Updates
Table 28. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 29. Novartis AG Major Business
Table 30. Novartis AG Acute Viral Rhinosinusitis Treatment Product and Services
Table 31. Novartis AG Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Novartis AG Recent Developments/Updates
Table 33. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 34. Teva Pharmaceutical Industries Ltd. Major Business
Table 35. Teva Pharmaceutical Industries Ltd. Acute Viral Rhinosinusitis Treatment Product and Services
Table 36. Teva Pharmaceutical Industries Ltd. Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 38. Sanofi Basic Information, Manufacturing Base and Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Acute Viral Rhinosinusitis Treatment Product and Services
Table 41. Sanofi Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Sanofi Recent Developments/Updates
Table 43. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 44. Abbott Laboratories Major Business
Table 45. Abbott Laboratories Acute Viral Rhinosinusitis Treatment Product and Services
Table 46. Abbott Laboratories Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Abbott Laboratories Recent Developments/Updates
Table 48. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 49. Bayer AG Major Business
Table 50. Bayer AG Acute Viral Rhinosinusitis Treatment Product and Services
Table 51. Bayer AG Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Bayer AG Recent Developments/Updates
Table 53. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 54. Eli Lilly and Company Major Business
Table 55. Eli Lilly and Company Acute Viral Rhinosinusitis Treatment Product and Services
Table 56. Eli Lilly and Company Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Eli Lilly and Company Recent Developments/Updates
Table 58. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 59. Bristol-Myers Squibb Major Business
Table 60. Bristol-Myers Squibb Acute Viral Rhinosinusitis Treatment Product and Services
Table 61. Bristol-Myers Squibb Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Bristol-Myers Squibb Recent Developments/Updates
Table 63. Merck & Co, Inc. Basic Information, Manufacturing Base and Competitors
Table 64. Merck & Co, Inc. Major Business
Table 65. Merck & Co, Inc. Acute Viral Rhinosinusitis Treatment Product and Services
Table 66. Merck & Co, Inc. Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Merck & Co, Inc. Recent Developments/Updates
Table 68. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 69. AstraZeneca plc Major Business
Table 70. AstraZeneca plc Acute Viral Rhinosinusitis Treatment Product and Services
Table 71. AstraZeneca plc Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. AstraZeneca plc Recent Developments/Updates
Table 73. Amneal Pharmaceuticals LLC Basic Information, Manufacturing Base and Competitors
Table 74. Amneal Pharmaceuticals LLC Major Business
Table 75. Amneal Pharmaceuticals LLC Acute Viral Rhinosinusitis Treatment Product and Services
Table 76. Amneal Pharmaceuticals LLC Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Amneal Pharmaceuticals LLC Recent Developments/Updates
Table 78. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 79. GlaxoSmithKline plc Major Business
Table 80. GlaxoSmithKline plc Acute Viral Rhinosinusitis Treatment Product and Services
Table 81. GlaxoSmithKline plc Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 82. GlaxoSmithKline plc Recent Developments/Updates
Table 83. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 84. Aurobindo Pharma Major Business
Table 85. Aurobindo Pharma Acute Viral Rhinosinusitis Treatment Product and Services
Table 86. Aurobindo Pharma Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 87. Aurobindo Pharma Recent Developments/Updates
Table 88. Hikma Pharmaceuticals plc Basic Information, Manufacturing Base and Competitors
Table 89. Hikma Pharmaceuticals plc Major Business
Table 90. Hikma Pharmaceuticals plc Acute Viral Rhinosinusitis Treatment Product and Services
Table 91. Hikma Pharmaceuticals plc Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 92. Hikma Pharmaceuticals plc Recent Developments/Updates
Table 93. Wockhardt Basic Information, Manufacturing Base and Competitors
Table 94. Wockhardt Major Business
Table 95. Wockhardt Acute Viral Rhinosinusitis Treatment Product and Services
Table 96. Wockhardt Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 97. Wockhardt Recent Developments/Updates
Table 98. Mylan N.V. Basic Information, Manufacturing Base and Competitors
Table 99. Mylan N.V. Major Business
Table 100. Mylan N.V. Acute Viral Rhinosinusitis Treatment Product and Services
Table 101. Mylan N.V. Acute Viral Rhinosinusitis Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 102. Mylan N.V. Recent Developments/Updates
Table 103. Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 104. Global Acute Viral Rhinosinusitis Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 105. Global Acute Viral Rhinosinusitis Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 106. Market Position of Manufacturers in Acute Viral Rhinosinusitis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 107. Head Office and Acute Viral Rhinosinusitis Treatment Production Site of Key Manufacturer
Table 108. Acute Viral Rhinosinusitis Treatment Market: Company Product Type Footprint
Table 109. Acute Viral Rhinosinusitis Treatment Market: Company Product Application Footprint
Table 110. Acute Viral Rhinosinusitis Treatment New Market Entrants and Barriers to Market Entry
Table 111. Acute Viral Rhinosinusitis Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 112. Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 113. Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 114. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 115. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 116. Global Acute Viral Rhinosinusitis Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 117. Global Acute Viral Rhinosinusitis Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 118. Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 119. Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 120. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 121. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 122. Global Acute Viral Rhinosinusitis Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 123. Global Acute Viral Rhinosinusitis Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 124. Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 125. Global Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 126. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 127. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 128. Global Acute Viral Rhinosinusitis Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 129. Global Acute Viral Rhinosinusitis Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 130. North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 131. North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 132. North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 133. North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 134. North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 135. North America Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 136. North America Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 137. North America Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 138. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 139. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 140. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 141. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 142. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 143. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 144. Europe Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 145. Europe Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 146. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 147. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 148. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 149. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 150. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 151. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 152. Asia-Pacific Acute Viral Rhinosinusitis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 153. Asia-Pacific Acute Viral Rhinosinusitis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 154. South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 155. South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 156. South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 157. South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 158. South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 159. South America Acute Viral Rhinosinusitis Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 160. South America Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 161. South America Acute Viral Rhinosinusitis Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 162. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 163. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 164. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 165. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 166. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 167. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 168. Middle East & Africa Acute Viral Rhinosinusitis Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 169. Middle East & Africa Acute Viral Rhinosinusitis Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 170. Acute Viral Rhinosinusitis Treatment Raw Material
Table 171. Key Manufacturers of Acute Viral Rhinosinusitis Treatment Raw Materials
Table 172. Acute Viral Rhinosinusitis Treatment Typical Distributors
Table 173. Acute Viral Rhinosinusitis Treatment Typical Customers
List of Figures
Figure 1. Acute Viral Rhinosinusitis Treatment Picture
Figure 2. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Type in 2022
Figure 4. NSAIDS Examples
Figure 5. Saline Nasal Spray Examples
Figure 6. Nasal Corticosteroids Examples
Figure 7. Decongestants Examples
Figure 8. Global Acute Viral Rhinosinusitis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Application in 2022
Figure 10. Offline Pharmacy Examples
Figure 11. E-Commerce Examples
Figure 12. Global Acute Viral Rhinosinusitis Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Acute Viral Rhinosinusitis Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Acute Viral Rhinosinusitis Treatment Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Acute Viral Rhinosinusitis Treatment Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Acute Viral Rhinosinusitis Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Acute Viral Rhinosinusitis Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Acute Viral Rhinosinusitis Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Acute Viral Rhinosinusitis Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Acute Viral Rhinosinusitis Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Acute Viral Rhinosinusitis Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 54. China Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Acute Viral Rhinosinusitis Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Acute Viral Rhinosinusitis Treatment Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Acute Viral Rhinosinusitis Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Acute Viral Rhinosinusitis Treatment Market Drivers
Figure 75. Acute Viral Rhinosinusitis Treatment Market Restraints
Figure 76. Acute Viral Rhinosinusitis Treatment Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Acute Viral Rhinosinusitis Treatment in 2022
Figure 79. Manufacturing Process Analysis of Acute Viral Rhinosinusitis Treatment
Figure 80. Acute Viral Rhinosinusitis Treatment Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
| 【急性ウイルス性鼻副鼻腔炎治療について】 ※急性ウイルス性鼻副鼻腔炎、一般的には「急性副鼻腔炎」や「風邪」とも呼ばれるこの病状は、ウイルスによって引き起こされる鼻と副鼻腔の炎症です。この炎症は、多くの場合、上気道感染、特に普通の風邪に続いて発症します。ウイルス性鼻副鼻腔炎は、通常、軽度から中等度の症状を伴う一過性の疾患であり、ほとんどの場合、適切な治療を受けることで自然に回復します。 急性ウイルス性鼻副鼻腔炎の主な原因は、風邪の原因となるウイルス、たとえばライノウイルス、アデノウイルス、インフルエンザウイルスなどです。これらのウイルスに感染すると、鼻の粘膜が炎症を起こし、腫れや分泌物の増加が見られます。その結果、鼻づまりや鼻水、喉の痛み、咳などの症状が現れます。 この疾患の特徴としては、まず症状の急激な発現が挙げられます。風邪を引いたり、ウイルスに感染したりしてから数日以内に症状が現れ、通常は1週間から10日で自然に回復します。主要な症状には、鼻づまり、鼻水、嗅覚の低下、顔面痛、頸部の不快感などがあります。これらの症状は非常に一般的であり、多くの人々が一度は経験するものです。また、全身症状としては、軽度の発熱や全身の倦怠感が伴うことがあります。 急性ウイルス性鼻副鼻腔炎は、一般的にウイルスに起因するため、抗生物質は効果的ではありません。そのため、治療は主に対症療法が中心となります。具体的には、痛みを和らげるための鎮痛剤、鼻の腫れを軽減するための点鼻薬や内服薬、十分な水分摂取、安静などが推奨されます。特に、鼻づまりに対しては生理食塩水のスプレーや蒸気吸入が有効とされています。 また、症状が重度であったり、合併症が疑われる場合には、医療機関を受診することが重要です。稀に、ウイルス性の鼻副鼻腔炎が細菌感染を合併することがあるため、注意が必要です。このような場合、適切な診断と治療が求められます。合併症としては、副鼻腔の感染や、中耳炎、さらには重篤な場合には脳の感染症なども考えられます。 急性ウイルス性鼻副鼻腔炎の種類には、症状の持続期間や重症度によって分類されることがあります。例えば、急性鼻副鼻腔炎は通常、発症から4週間以内に症状が改善するものを指し、慢性鼻副鼻腔炎は12週間以上症状が続くものです。急性ウイルス性鼻副鼻腔炎は、多くの場合、風邪に続いて現れるため、上気道感染の一部とみなされることが多いです。 この感染症に関連する技術的な側面には、診断手法と治療法があります。診断は、通常は医師による視診や症状の確認に基づいて行われますが、必要に応じてCTスキャンやMRIなどの画像診断が行われることもあります。また、症状が長引く場合には、鼻腔内の視察や内視鏡検査が必要になることもあります。これによって、鼻づまりの原因や合併症の有無を確認することができます。 一方、治療においては、最近では新たな治療法や管理方法が研究されています。たとえば、免疫療法やワクチン開発なども現在進行中の研究テーマです。これにより、将来的にはより効果的な予防策や治療法が実現する可能性があります。 急性ウイルス性鼻副鼻腔炎は非常に一般的な病状であるため、幅広い人々に影響を与えます。特に、寒い季節や花粉の飛散時期など、ウイルス活動が活発な時期には、発症リスクが高まります。予防策としては、十分な休息と栄養の摂取、手洗いやマスク着用により、ウイルス感染を防ぐことが重要です。また、感染者との接触を避けることや、咳エチケットを守ることも広がりを防ぐ手段となります。 総じて、急性ウイルス性鼻副鼻腔炎は、その軽快性や一過性の特徴から過小評価されがちですが、時には合併症を引き起こすこともあるため、適切な知識と対策が求められます。理解を深め、早期の診断と治療を行うことで、多くの人にとって快適な日常生活を取り戻すことができるでしょう。 |
